跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
BANZEL - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
BANZEL
Authorized
STANDARD
BANZEL
EISAI LIMITED
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
5f78d8962111a865
Company
EISAI LIMITED
Type
Standard
Approval Details
Approval Id
5f78d8962111a865
Drug Approval Canada Name
BANZEL
Product Name
BANZEL
Status
Cancelled Pre Market
Status Date
2020-04-27
Din
02388685
Drug Class
Human
Dosage Form
Suspension
Route Of Administration
Oral
Schedule
Prescription
Ahfs
28:12.92
Atc Original
N03AF03 RUFINAMIDE
Atc Name
n 03 af 03
Aig Number
0152938004
Company Name
EISAI LIMITED
Company Address
6925 Century Ave, Suite 701, Mississauga, Ontario, Canada, L5N 7K2
Company Detail Path
/organization/eisai-limited
Company Information
Pharmaceutical Company Name
EISAI LIMITED
Country Name
Ireland
Address
TEN EARLSFORT TERRACE
Active Ingredients
RUFINAMIDE
40 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
5f78d8962111a865
Type
Standard
Back to Health Canada Approvals